CRISPR Therapeutics AG vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends

Biotech Giants' SG&A Expenses: A Decade of Strategic Shifts

__timestampAgios Pharmaceuticals, Inc.CRISPR Therapeutics AG
Wednesday, January 1, 2014191200005114000
Thursday, January 1, 20153599200013403000
Friday, January 1, 20165071400031056000
Sunday, January 1, 20177112400035845000
Monday, January 1, 201811414500048294000
Tuesday, January 1, 201913203400063488000
Wednesday, January 1, 202014907000088208000
Friday, January 1, 2021121445000102802000
Saturday, January 1, 2022121673000102464000
Sunday, January 1, 202311990300076162000
Monday, January 1, 202415678400072977000
Loading chart...

Igniting the spark of knowledge

SG&A Expense Trends: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: Agios Pharmaceuticals, Inc. and CRISPR Therapeutics AG, from 2014 to 2023.

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals has shown a steady increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. This growth reflects their aggressive expansion and investment in administrative capabilities.

CRISPR Therapeutics AG

CRISPR Therapeutics, known for its groundbreaking gene-editing technology, also saw a significant increase in SG&A expenses, with a 1,900% surge by 2021. However, a notable decline in 2023 suggests a strategic shift or cost optimization.

Conclusion

These trends highlight the contrasting strategies of these biotech giants, offering insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025